Biotinylated Cynomolgus HLA-G&B2M&Peptide (RIIPRHLQL) Monomer Protein, Active
Beta LifeScience
SKU/CAT #: BLK-00508P-100UG
Biotinylated Cynomolgus HLA-G&B2M&Peptide (RIIPRHLQL) Monomer on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
Biotinylated Cynomolgus HLA-G&B2M&Peptide (RIIPRHLQL) Monomer Protein, Active
Beta LifeScience
SKU/CAT #: BLK-00508P-100UG
Collections: Fc receptors, Recombinant proteins
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Description | Recombinant Biotinylated Cynomolgus HLA-G&B2M&Peptide (RIIPRHLQL) Monomer Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus.It contains Gly25-Thr305(HLA-G),Ile21-Met119(B2M) and RIIPRHLQL peptide. |
Purity | > 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC |
Accession | E0WKX9(HLA-G)&Q8SPW0(B2M)&RIIPRHLQL |
Target Symbol | HLA-G&B2M&Peptide (RIIPRHLQL) Monomer |
Species | Cynomolgus |
Expression System | HEK293 |
Tag | C-His-Avi |
Expression Range | Gly25-Thr305(HLA-G), Ile21-Met119(B2M)and RIIPRHLQL peptide |
Mol. Weight | The protein has a predicted MW of 50.6 kDa. Due to glycosylation, the protein migrates to 55-65 kDa based on Tris-Bis PAGE result. |
Form | Lyophilized |
Formulation | Lyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
Endotoxin | Less than 1EU per ug by the LAL method. |
Activity | The affinity constant of 0.13 uM as determined in SPR assay (Biacore T200). Contact us for detailed testing images. |
Storage | Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
Shipping | Shipped at ambient temperature. |
Gene Background | HLA-G is a molecule that was first known to confer protection to the fetus from destruction by the immune system of its mother, thus critically contributing to fetal-maternal tolerance. The first functional finding constituted the basis for HLA-G research and can be summarized as such: HLA-G, membrane-bound or soluble, strongly binds its inhibitory receptors on immune cells (NK, T, B, monocytes/dendritic cells), inhibits the functions of these effectors, and so induces immune inhibition. |